Blood transfusion = Trasfusione del sangue Journal Impact Factor & Information

Publisher: Società italiana di medicina trasfusionale e immunoematologia

Current impact factor: 2.37

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.372
2013 Impact Factor 1.901
2012 Impact Factor 1.858
2011 Impact Factor 2.099
2010 Impact Factor 2.519

Impact factor over time

Impact factor

Additional details

5-year impact 2.24
Cited half-life 2.70
Immediacy index 0.66
Eigenfactor 0.00
Article influence 0.54
Other titles Trasfusione del sangue
ISSN 1723-2007
OCLC 61860963
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Critically ill patients appear to be at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism during their stay in the intensive care unit (ICU). However, little is known about the clinical course of venous thromboembolism in the ICU setting. We therefore evaluated, through a systematic review of the literature, the available data on the impact of a diagnosis of DVT on hospital and ICU stay, duration of mechanical ventilation and mortality in critically ill patients. We also tried to determine whether currently adopted prophylactic measures need to be revised and improved in the ICU setting. Materials and methods: MEDLINE and EMBASE databases were searched up to week 4 of June 2012. Two reviewers selected studies and extracted data. Pooled results are reported as relative risks and weighted mean differences and are presented with 95% confidence intervals (CI). Results: Seven studies for a total of 1,783 patients were included. A diagnosis of DVT was frequent in these patients with a mean rate of 12.7% (95% CI: 8.7-17.5%). DVT patients had longer ICU and hospital stays compared to those without DVT (7.28 days; 95% CI: 1.4-13.15; and 11.2 days; 95% CI: 3.82-18.63 days, respectively). The duration of mechanical ventilation was significantly increased in DVT patients (weighted mean difference: 4.85 days; 95% CI: 2.07-7.63). DVT patients had a marginally significant increase in the risk of hospital mortality (relative risk 1.31; 95% CI: 0.99-1.74; p=0.06), and a not statistically significant increase in the risk of ICU mortality (RR 1.64; 95% CI: 0.91-2.93; p=0.10). Conclusions: A diagnosis of DVT upon ICU admission appears to affect clinically important outcomes including duration of ICU and hospital stay and hospital mortality. Larger, prospective studies are warranted.
    Blood transfusion = Trasfusione del sangue 10/2015; 13(4):559-568. DOI:10.2450/2015.0277-14

  • Blood transfusion = Trasfusione del sangue 10/2015; 13(4):539. DOI:10.2450/2015.0256-15
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Enzymatic conversion of blood group A1B red blood cells (RBC) to group O RBC (ECO) was achieved by combined treatment with α-galactosidase and α-N-acetylgalactosaminidase. The aim of this study was to evaluate the function and safety of these A1B-ECO RBC in vitro. Materials and methods: A 20% packed volume of A1B RBC was treated with enzymes in 250 mM glycine buffer, pH 6.8. The efficiency of the conversion of A and B antigen was evaluated by traditional typing in test tubes, gel column agglutination technology and fluorescence-activated cell sorting (FACS) analysis. The physiological and metabolic parameters of native and ECO RBC were compared, including osmotic fragility, erythrocyte deformation index, levels of 2,3-diphosphoglycerate, ATP, methaemoglobin, free Na(+), and free K(+). The morphology of native and ECO RBC was observed by scanning electron microscopy. Residual α-galactosidase or α-N-acetylgalactosaminidase in A1B-ECO RBC was detected by double-antibody sandwich ELISA method. Manual cross-matching was applied to ensure blood compatibility. Results: The RBC agglutination tests and FACS results showed that A1B RBC were efficiently converted to O RBC. Functional analysis suggested that the conversion process had little impact on the physiological and metabolic parameters of the RBC. The residual amounts of either α-galactosidase or α-N-acetylgalactosaminidase in the A1B-ECO RBC were less than 10 ng/mL of packed RBC. About 18% of group B and 55% of group O sera reacted with the A1B-ECO RBC in a sensitive gel column cross-matching test. Discussion: The conversion process does not appear to affect the morphological, physiological or metabolic parameters of A1B-ECO RBC. However, the A1B-ECO RBC still reacted with some group O and B sera, which may partly reflect the complexity of group A1 antigens. More research on the safety of A1B-ECO RBC is necessary before the application of these RBC in clinical transfusion.
    Blood transfusion = Trasfusione del sangue 10/2015; DOI:10.2450/2015.0010-15

  • Blood transfusion = Trasfusione del sangue 10/2015; DOI:10.2450/2015.0044-15
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of specific autoantibodies against naturally occurring factor VIII (FVIII). Although about half of cases are idiopathic, AHA may be associated with several non-neoplastic conditions, autoimmune disorders, as well as haematological malignancies, such as chronic lymphocytic leukaemia and lymphoma. The long-term suppression of inhibitors is one of the mainstays of the treatment of AHA. Apart from standard immunosuppressive treatments, rituximab has been proven to be effective in AHA. Materials and methods: The aim of this review is to provide a systematic description of data available in the literature on this topic. To do so, we performed a search using the indexed online database Medline/PubMed, without temporal limits, matching the words "rituximab" and "acquired h(a)emophilia". Furthermore, additional published studies were identified in the reference list of the publications found in PubMed. Results: The review of the literature confirms that rituximab may be a safe and useful treatment for AHA. Discussion: Although rituximab is not a standard therapy for AHA, it may be useful in resistant cases. However, the definitive place of this monoclonal antibody in the therapeutic strategy for AHA (first or second-line, alone or in combination with other drugs) remains to be determined more precisely and warrants further investigation.
    Blood transfusion = Trasfusione del sangue 10/2015; DOI:10.2450/2015.0090-15
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Molecular-based laboratory tests can predict blood group antigens and supplement serological methods, adding a unique technology to assist in resolving discrepant or incomplete blood group typing or antibody identification. Hospital transfusion services have options for integrating molecular-based methods in their routine operations. We describe here the model of a hospital-reference laboratory partnership. Materials and methods: Blood samples for compatibility testing were obtained from patients in a 609-bed hospital serving an urban multiethnic and multiracial population. When results of blood group phenotyping by serological methods were inconclusive, samples were referred for molecular-based testing. The reference laboratory used several methods for genotyping, including polymerase chain reaction followed by restriction enzyme-linked polymorphism analysis, sequence-specific primer polymerase chain reaction and array-based approaches. Human erythrocyte antigen, RHCE and RHD single nucleotide polymorphism arrays were integrated into the laboratory as they became commercially available. Results: The hospital-reference laboratory model made it possible to integrate blood group genotyping promptly by current technology without the expense of new laboratory equipment or adding personnel with technical expertise. We describe ten cases that illustrate the categories of serological problems that were resolved by molecular methods. Discussion: In-hospital molecular testing for transfusion services has logistical advantages, but is financially impractical for most hospitals. Our model demonstrates the advantages of a hospital-reference laboratory partnership. In conclusion, hospital transfusion services can integrate molecular-based testing in their routine services without delay by establishing a partnership with a molecular blood group reference laboratory. The hospital reference-laboratory model promotes genomic medicine without the expense of new equipment and skilled personnel, while supporting the economy of centralised large-scale laboratory operations.
    Blood transfusion = Trasfusione del sangue 10/2015; DOI:10.2450/2015.0070-15

  • Blood transfusion = Trasfusione del sangue 10/2015; 13(3):484-497. DOI:10.2450/2015.0113-15
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Radiotherapy is associated with the development of severe complications, such as secondary acute myeloid leukaemia (AML) and myelodisplasia (MDS), chronic skin infection and in some cases even skin cancers. Less aggressive complications include radiodermatitis. These are skin disorders due to exposure to x- or γ-rays causing ionization of tissue water, leading to skin changes resembling burn injuries. These lesions are aesthetically quite disfiguring and can lead to significant psychosocial stress, particularly for women. Case report and Results We report on the first case of severe radiodermitis with successful restitution ab integro by repeated administration of platelet-gel (PLT-gel) and treatments with hyperbaric chamber. Conclusions The future possibility of using cord blood PLT-gel should also be considered and where possible tested.
    Blood transfusion = Trasfusione del sangue 10/2015;

  • Blood transfusion = Trasfusione del sangue 07/2015; DOI:10.2450/2015.0034-15

  • Blood transfusion = Trasfusione del sangue 07/2015; DOI:10.2450/2015.0072-15
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are limited published data on the characteristics of blood transfusion recipients in sub-Saharan Africa. This study describes the demographic characteristics of blood transfusion recipients and patterns of blood and blood component use in Zimbabwe. Data on the characteristics of the blood transfusion recipients (age, sex, blood group), blood components received (type, quantity), discharge diagnoses and outcomes following transfusion (discharge status, duration of stay in hospital), were retrospectively collected from four major hospitals for the period from January 1, 2012 to December 31, 2012. Diagnoses were grouped into broad categories according to the disease headings of the International Classification of Diseases (ICD-10). Surgical procedures were grouped into broad categories according to organ system using ICD-9. Most of the 1,793 transfusion recipients studied were female (63.2%) and in the reproductive age group, i.e. 15-49 years (65.3%). The median age of the recipients was 33 years (range, 0-93). The majority of these recipients (n=1,642; 91.6%) received a red blood cell transfusion. The majority of the patients were diagnosed with conditions related to pregnancy and childbirth (22.3%), and diseases of blood and blood-forming organs (17.7%). The median time spent in hospital was 8 days (range, 0-214) and in-hospital mortality was 15.4%. Our sample of blood transfusion recipients were fairly young and most of them received red blood cell transfusions. The majority of patients in the reproductive age group received blood transfusions for pregnancy and childbirth-related diagnoses.
    Blood transfusion = Trasfusione del sangue 07/2015; DOI:10.2450/2015.0019-15